Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.154
Buy
RSI(14)
59.997
Neutral
STOCH(KDJ)(9,3,3)
34.509
Sell
ATR(14)
0.958
High Vlolatility
CCI(14)
7.201
Neutral
Williams %R
44.021
Buy
TRIX(12,20)
1.951
Sell
StochRSI(14)
0.000
Oversold
Search
Fortrea Holdings Inc
FTREAdd to Watchlist
13.660USD
-0.580-4.07%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.29BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Fortrea Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
Fortrea Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 21 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.55.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fortrea Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Fortrea Holdings Inc Highlights
StrengthsRisks
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.72B.
Fairly Valued
The company’s latest PE is -2.84, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 98.32M shares, decreasing 20.39% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.19K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
16.550
Target Price
+16.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Fortrea Holdings Inc is 6.67, ranking 214 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 636.50M, representing a year-over-year decrease of 2.27%, while its net profit experienced a year-over-year decrease of 95.81%.
Score
Financials
5.03
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
3.53
Operational Efficiency
10.00
Growth Potential
7.53
Shareholder Returns
7.28
Fortrea Holdings Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Fortrea Holdings Inc is 8.81, ranking 16 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.84, which is -2071.59% below the recent high of 55.90 and -4889.16% above the recent low of -141.45.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 21/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Fortrea Holdings Inc is 7.09, ranking 311 out of 382 in the Biotechnology & Medical Research industry. The average price target is 11.50, with a high of 15.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
16.550
Target Price
+16.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Fortrea Holdings Inc
FTRE
11
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Fortrea Holdings Inc is 8.97, ranking 42 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 16.84 and the support level at 9.84, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
14.394
Sell
MA10
14.539
Sell
MA20
12.584
Buy
MA50
10.731
Buy
MA100
12.735
Buy
MA200
11.588
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Fortrea Holdings Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.93%, representing a quarter-over-quarter decrease of 14.79%. The largest institutional shareholder is James Simons, holding a total of 1.43M shares, representing 1.51% of shares outstanding, with 255.52% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fortrea Holdings Inc is 4.11, ranking 100 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+51.79%
240-Day Volatility
+91.97%
Return
Best Daily Return
60 days
+18.61%
120 days
+18.61%
5 years
--
Worst Daily Return
60 days
-8.95%
120 days
-15.22%
5 years
--
Sharpe Ratio
60 days
+1.92
120 days
+1.22
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+51.79%
3 years
+89.92%
5 years
--
Return-to-Drawdown Ratio
240 days
+4.46
3 years
-0.23
5 years
--
Skewness
240 days
+0.80
3 years
+0.47
5 years
--
Volatility
Realised Volatility
240 days
+91.97%
5 years
--
Standardised True Range
240 days
+5.93%
5 years
--
Downside Risk-Adjusted Return
120 days
+186.98%
240 days
+186.98%
Maximum Daily Upside Volatility
60 days
+68.02%
Maximum Daily Downside Volatility
60 days
+59.64%
Liquidity
Average Turnover Rate
60 days
+1.68%
120 days
+1.68%
5 years
--
Turnover Deviation
20 days
-9.99%
60 days
-14.10%
120 days
-14.22%
Peer Comparison
Biotechnology & Medical Research
Fortrea Holdings Inc
FTRE
7.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
